Navigation Links
P&G Response to FDA Approval of Prevacid OTC(R) 24HR
Date:5/14/2009

CINCINNATI, May 14 /PRNewswire/ -- In response to the FDA's approval of Prevacid OTC(R) 24HR, The Procter & Gamble Company issued the following statement:

(Photo: http://www.newscom.com/cgi-bin/prnh//NY17325 )

"Prilosec OTC(R) is the #1 doctor and pharmacist recommended over-the-counter heartburn remedy in the U.S.," said Tim Brown - General Manager, P&G Personal Health Care North America. "Procter & Gamble built the OTC PPI market and since 2003, millions of consumers have made Prilosec OTC their frequent heartburn remedy of choice. We don't expect that to change given our strong record of providing all day and all night heartburn relief with just one pill a day."

Procter & Gamble (P&G) is a leader in gastrointestinal health and is committed to meeting the needs of its consumers with innovative digestive wellness treatments, including top-selling brands such as ALIGN(R), ASACOL(R), METAMUCIL(R), PRILOSEC OTC(R) and PEPTO-BISMOL(R).

About PRILOSEC OTC

PRILOSEC OTC is the #1 Doctor recommended acid reducer+ and Pharmacist recommended OTC Heartburn medicine++, the first of a class of OTC heartburn medicines that treats frequent heartburn with just one pill a day, unlike most over the counter heartburn medication. Prilosec OTC is the only OTC leading heartburn medicine that can work for 24 hours with one pill a day by directly shutting down many acid pumps in your stomach when used as directed for 14 days for the treating of frequent heartburn. PRILOSEC OTC is the #1 selling OTC heartburn medicine* on the market. For more information about PRILOSEC OTC, visit www.prilosecotc.com. PRILOSEC OTC is available over-the-counter through an alliance between P&G and AstraZeneca.

About Procter & Gamble (NYSE: PG)

Three billion times a day, P&G brands touch the lives of people around the world. P&G has one of the strongest portfolios of quality, leadership brands in consumer health and wellness, including Actonel(R), Align(R), Always(R), Asacol(R), Crest(R), Enablex(R), Metamucil(R), Oral-B(R), Pepto-Bismol(R), Prilosec OTC(R), Scope(R), Tampax(R), and Vicks(R), in addition to its trusted consumer brands, including Ariel(R), Braun(R), Bounty(R), Charmin(R), Dawn(R), Downy(R), Duracell(R), Folgers(R), Gillette(R), Head & Shoulders(R), Iams(R), Lenor(R), Mach3(R), Olay(R), Pantene(R), Pampers(R), Pringles(R), Tide(R), Wella(R), and Whisper(R). The P&G community consists of over 135,000 employees working in over 80 countries worldwide. Please visit http://www.pg.com for the latest news and in-depth information about P&G and its brands.

    Contact:
    P&G Health Care External Relations
    Carlos Taveras
    513-622-4645
    Taveras.cm@pg.com

    MS&L Worldwide
    Robyn Finker
    212-468-3879
    Robyn.Finker@mslworldwide.com

++ Pharmacy Times, OTC Supplement, June 2007

* Wolters Kluwer Health, Wolters Kluwer Health Physician Recommendation Audit (April 2004-June 2007, Acid Reducer Category). Data on file.


'/>"/>
SOURCE Procter & Gamble
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
2. Study identifies key player in the bodys immune response to chronic stress
3. Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911.
4. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
5. Merck & Co., Inc. Response to Todays New York Medicaid Suit
6. Maternal depression and controlling behavior associated with increased stress response in infants
7. Family history of alcoholism affects response to drug used to treat heavy drinking
8. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
9. Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer
10. PET scans can accurately detect a breast tumors response to chemotherapy
11. DNA damage response confers a barrier for viral tumorigenesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... 2016 , ... Research has shown that building shame resilience ... and level of relapse. , At the 2016 iaedp Symposium, the ... the critical tasks of the recovery phase and beyond including relapse prevention and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
(Date:2/5/2016)... City, UT (PRWEB) , ... February 05, 2016 , ... ... Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist in ... Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV show, ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology: